Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency Signature

PURPOSE: Poly ADP-ribose polymerase inhibitors (PARPi) are approved for patients with human epidermal growth factor receptor 2–negative metastatic breast cancer (mBC) and germline pathogenic/likely pathogenic variant (hereafter mutation) in the BRCA1/2 genes (gBRCA); however, clinical benefit has al...

Descripción completa

Detalles Bibliográficos
Autores principales: Batalini, Felipe, Madison, Russell W., Sokol, Ethan S., Jin, Dexter X., Chen, Kuei-Ting, Decker, Brennan, Pavlick, Dean C., Frampton, Garrett M., Wulf, Gerburg M., Garber, Judy E., Oxnard, Geoffrey, Schrock, Alexa B., Tung, Nadine M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681426/
https://www.ncbi.nlm.nih.gov/pubmed/37992259
http://dx.doi.org/10.1200/PO.23.00091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10681426/
https://www.ncbi.nlm.nih.gov/pubmed/37992259
http://dx.doi.org/10.1200/PO.23.00091

Ejemplares similares